Scientists test new drug to weaken ovarian cancer before surgery
NCT ID NCT02659241
Summary
This early study is testing if a drug called adavosertib, given before surgery, can affect the DNA of tumors in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goal is to learn how the drug changes the cancer cells at a molecular level, which may help doctors understand how to plan better treatments in the future. It involves 38 participants who take the drug orally for a short period before their standard surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson League City
League City, Texas, 77573, United States
-
MD Anderson West Houston
Houston, Texas, 77079, United States
-
MD Anderson in Sugar Land
Sugar Land, Texas, 77478, United States
-
MD Anderson in The Woodlands
Conroe, Texas, 77384, United States
-
Memorial Hermann Memorial City Medical Center
Houston, Texas, 77024, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
-
The Woman's Hospital of Texas
Houston, Texas, 77054, United States
Conditions
Explore the condition pages connected to this study.